{"schema_version":"secwatch.filing_event.v1","accession":"0000944809-22-000041","form_type":"8-K","ticker":"OPK","cik":"0000944809","company_name":"OPKO HEALTH, INC.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.730560+00:00","generated_at":"2026-06-24T04:45:14.559666+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"OPKO Health Q2 net loss of $101.7M on $309.9M revenue; NGENLA launch, ModeX acquisition","bullets":["Acquired ModeX for $300M in stock; Dr. Zerhouni appointed President/Vice Chairman, Dr. Nabel Chief Innovation Officer.","Pfizer launched NGENLA in Europe/Japan; OPKO received $85M milestone payment.","Closed GeneDx sale to Sema4 for ~$322M upfront (cash + shares) plus up to $150M milestones.","BRL diagnostics revenue fell to $186.8M from $397.2M; COVID PCR tests dropped to 0.9M from 2.8M.","Net loss includes $71.2M non-cash charge from Sema4 stock decline; operating loss of $10.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0000944809-22-000041","json":"https://secwatch.observer/filing/0000944809-22-000041.json","markdown":"https://secwatch.observer/filing/0000944809-22-000041.md","text":"https://secwatch.observer/filing/0000944809-22-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/944809/000094480922000041/0000944809-22-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/944809/000094480922000041/opk-20220804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:45:14.559666+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}